Safety profile of azvudine in COVID-19 patients with renal impairment: a retrospective analysis
Frontiers in Pharmacology · 29.06.2026 · 17
DOI: 10.3389/fphar.2026.1830085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.06.2026. Verfasst von Xiaomin Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Fifth Affiliated Hospital of Zunyi Medical, University, Zhuhai (Zhuhai Sixth People's Hospital), Zhuhai, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Azvudine (FNC), an antiviral drug approved in China for the treatment of Coronavirus disease 2019 (COVID-19) infection, has not yet established a well-defined safety profile in patients with renal impairment. This study aimed to evaluate the safety of using FNC in patients with renal impairment.
Methods
We conducted a retrospective analysis of clinical data from 328 COVID-19 patients to assess FNC-related adverse drug events (ADEs). Patients were stratified into two cohorts: a control group with an estimated glomerular filtration rate (eGFR) > 70 mL/min/1.73 m 2 and a study group with eGFR ≤70 mL/min/1.73 m 2 . Our main objective was to assess whether there were any differences in the incidence of ADEs between the two groups. Secondly, we attempted to develop predictive models for ADEs that were frequent and closely related to the eGFR grade.
Results
Over half of the cohort (51.8%) experienced FNC-associated ADEs, predominantly hepatic function abnormalities (36.6%) and renal function abnormalities (18.9%). The incidence of acute kidney injury (AKI) was 8.8%. Patients with renal impairment exhibited a higher risk of ADEs, particularly among elderly individuals and patients with a high neutrophil count. No differences in hepatic function abnormalities were found between the two groups. Patients with renal impairment had a higher risk of renal function abnormalities and AKI, with decreased eGFR identified as an independent risk factor for these ADEs. The predictors included in the nomogram model for AKI were neutrophil count and eGFR grade. The nomogram model demonstrated predictive performance and calibration, with an area under the curve of 0.812.
Conclusion
These findings highlight the need for enhanced safety monitoring and potential dose adjustments when administering FNC to COVID-19 patients with renal impairment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, The Fifth Affiliated Hospital of Zunyi Medical, University, Zhuhai (Zhuhai Sixth People's Hospital), Zhuhai, China.
- Department of Pharmacy, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, China.
- Department of Pharmacy, Guangzhou Twelfth People's Hospital, Guangzhou, China.
Zitieren
APA
Zhang, X., Qian, J., Cui, J., Luo, Y., Huang, S., & Wen, Z. (2026). Safety profile of azvudine in COVID-19 patients with renal impairment: a retrospective analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1830085
Vancouver
Zhang X, Qian J, Cui J, Luo Y, Huang S, Wen Z. Safety profile of azvudine in COVID-19 patients with renal impairment: a retrospective analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1830085
BibTeX
@article{Zhang2026,
author = {Zhang, Xiaomin and Qian, Jiajian and Cui, Jiawen and Luo, Yuhong and Huang, Sichao and Wen, Zhiyong},
title = {Safety profile of azvudine in COVID-19 patients with renal impairment: a retrospective analysis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1830085}
}
EUVIMED